Ocugen Inc Dossier - Source-backed chat

Ocugen Inc

OCGNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.80

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.00Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $339.1M

Enterprise Value $240.8M

Shares Outstanding 339.1M diluted

Next Earnings Date31 Mar 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Ocugen is transitioning from a speculative clinical-stage biotech to a late-stage gene therapy leader with a highly differentiated, mutation-agnostic modifier platform. By targeting nuclear hormone receptors (NR2E3 and RORA) to restore cellular homeostasis, Ocugen's candidates (OCU400, OCU410, and OCU410ST) address broad patient populations rather than single-mutation cohorts. With enrollment completed for its Phase 3 retinitis pigmentosa (RP) and Phase 2/3 Stargardt disease trials, and a massive $115M convertible note financing extending its cash runway into 2028, Ocugen is well-positioned to deliver multiple high-impact clinical and regulatory catalysts over the next 12-24 months.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.00

Mean target$11.43

High · most bullish analyst$22.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

OCU400's Phase 3 trial fails to meet its primary endpoint of visual function improvement, or encounters severe safety/tolerability issues, invalidating the modifier gene therapy platform. Regulatory delays push back BLA submissions, and high cash burn forces highly dilutive equity offerings as the convertible debt obligations loom. Competitors with optogenetic or single-gene therapies capture the market, leaving Ocugen's pipeline impaired.

Base CaseCentral scenario

OCU400 successfully completes its Phase 3 liMeliGhT trial, demonstrating robust efficacy and safety in a mutation-agnostic RP population. Topline data in Q1 2027 supports a successful BLA approval in late 2027 or early 2028. OCU410ST shows positive interim and topline results, leading to a BLA filing in mid-2027. OCU410 enters Phase 3 for geographic atrophy (GA) in Q3 2026, establishing a multi-billion dollar market opportunity. The $115M convertible note financing successfully funds operations through these key readouts without immediate dilutive equity raises.

Bull CaseUpside scenario

Ocugen's bull case centers on a synchronized late-stage ophthalmology pipeline built around one-time modifier gene therapies for retinal diseases with large unmet needs. The lead asset, OCU400, is in a Phase 3 study for retinitis pigmentosa with a rolling BLA targeted for Q3 2026 and top-line data expected in Q1 2027. Additionally, OCU410ST (Stargardt disease) has completed enrollment in its Phase 2/3 study with interim data expected in Q3 2026, and OCU410 (geographic atrophy) is preparing to enter Phase 3 in Q3 2026. Near-term financial risk has been significantly mitigated by a $130 million convertible senior notes financing in May 2026, which extends the company's cash runway into 2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Mutation-Agnostic Platform: Modifier gene therapy approach addresses broad disease pathways, bypassing the limitations of single-gene replacement therapies.
Late-Stage Pipeline: Lead asset OCU400 is in Phase 3 with completed enrollment, and OCU410ST is in a pivotal Phase 2/3 trial.
Strong Clinical Signals: OCU410 Phase 2 data demonstrated a statistically significant 31% reduction in GA lesion growth at the optimal dose.
Extended Cash Runway: Recent $115M convertible note offering and debt restructuring extend the company's cash runway into 2028, covering major clinical readouts.

Key Investment Risks

Clinical Trial Failure: High risk of failure inherent to late-stage gene therapy trials.
Regulatory Hurdles: Potential delays in FDA rolling BLA submissions or Phase 3 trial designs.
Financial Leverage: The issuance of $115M in convertible senior notes introduces long-term debt obligations and potential future equity dilution.

Thesis Invalidation Triggers

Failure of OCU400 Phase 3 liMeliGhT trial to meet its primary endpoint in Q1 2027.
Negative interim outcome analysis for OCU410ST in Q3 2026.
Inability to reach regulatory agreement with the FDA/EMA for OCU410 Phase 3 trial design in Q3 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.